|
Active substance |
inotuzumab ozogamicin |
|
Holder |
Pfizer |
|
Status |
Closed |
|
Indication |
relapsed or refractory CD22-positive B-Cell precursor acute lymphoblastic leukemia (ALL) in adult patients |
|
Public documents |
|
|
Last update |
31/07/2019 |
Besponsa®
Last updated on 10/09/2024